# A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

> **NCT02279433** · PHASE1 · COMPLETED · sponsor: **Nuvation Bio Inc.** · enrollment: 46 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** DS6051b

## Key facts

- **NCT ID:** NCT02279433
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279433, "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02279433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*